UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 8 von 10
Datensatz exportieren als...
BibTeX
Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention
Catheterization and cardiovascular interventions, 2013-10, Vol.82 (4), p.604-611
Pyxaras, Stylianos A.
Mangiacapra, Fabio
Verhamme, Katia
Di Serafino, Luigi
De Vroey, Frederic
Toth, Gabor
Perkan, Andrea
Salvi, Alessandro
Bartunek, Jozef
De Bruyne, Bernard
Wijns, William
Sinagra, Gianfranco
Barbato, Emanuele
2013
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Pyxaras, Stylianos A.
Mangiacapra, Fabio
Verhamme, Katia
Di Serafino, Luigi
De Vroey, Frederic
Toth, Gabor
Perkan, Andrea
Salvi, Alessandro
Bartunek, Jozef
De Bruyne, Bernard
Wijns, William
Sinagra, Gianfranco
Barbato, Emanuele
Titel
Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention
Ist Teil von
Catheterization and cardiovascular interventions, 2013-10, Vol.82 (4), p.604-611
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
Background Previous studies failed to assess the individual prognostic role of thrombus aspiration (TA) or abciximab in primary percutaneous coronary intervention (pPCI), due their prevalent combined use. Methods and Results A total of 644 consecutive ST‐segment elevation myocardial infarction patients treated with pPCI were included in this retrospective registry from January 2006 to December 2008. Patients were divided in: (a) Group 1, with conventional pPCI; (b) Group 2, with pPCI and abciximab; (c) Group 3, with pPCI and TA; (d) Group 4, with pPCI and abciximab plus TA. Primary end point was the composite of major adverse cardiovascular events (MACEs, defined as overall mortality, myocardial infarction, target vessel revascularization, and major bleedings) at 1 year. Baseline clinical and angiographic characteristics were not different among the groups, with the exception of a younger age in group 4. The two groups of patients treated with TA (group 3 and 4) received more frequently direct stenting (P < 0.001 vs. group 1 for both), presented higher rate of end‐procedural TIMI flow grade 3 (P < 0.001 vs. group 1 for both), and lower rate of no‐reflow (P = 0.016 and P < 0.001 vs. group 1, respectively). Patients of group 2 presented a borderline nonsignificant trend toward higher rate of end‐procedural TIMI flow grade 3 (P = 0.083 vs. group 1). MACEs at 1 year were 43 (29%) in group 1 versus 25 (22%) in group 2 versus 24 (19%) in group 3 versus 32 (13%) in group 4 (log‐rank P = 0.001). At the multivariate Cox regression analysis, combined TA plus abciximab in group 4 [hazard ratio (HR): 0.48, confidence interval (CI) 95% 0.28–0.84, P = 0.01] and a higher left ventricular ejection fraction (HR: 0.97, CI 95% 0.95–0.98, P < 0.001) were significantly associated with lower MACE rate. Conclusions The combination of pharmacologic and mechanic antithrombotic treatment during pPCI was associated with better 1‐year clinical outcome. © 2013 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 1522-1946
eISSN: 1522-726X
DOI: 10.1002/ccd.24837
Titel-ID: cdi_proquest_miscellaneous_1438569058
Format
–
Schlagworte
abciximab
,
Aged
,
Aged, 80 and over
,
Antibodies, Monoclonal - adverse effects
,
Antibodies, Monoclonal - therapeutic use
,
Chi-Square Distribution
,
Combined Modality Therapy
,
Coronary Thrombosis - diagnosis
,
Coronary Thrombosis - mortality
,
Coronary Thrombosis - therapy
,
Female
,
Fibrinolytic Agents - adverse effects
,
Fibrinolytic Agents - therapeutic use
,
Hemorrhage - chemically induced
,
Humans
,
Immunoglobulin Fab Fragments - adverse effects
,
Immunoglobulin Fab Fragments - therapeutic use
,
Kaplan-Meier Estimate
,
Male
,
Middle Aged
,
Multivariate Analysis
,
Myocardial Infarction - diagnosis
,
Myocardial Infarction - mortality
,
Myocardial Infarction - therapy
,
Percutaneous Coronary Intervention - adverse effects
,
Percutaneous Coronary Intervention - mortality
,
primary percutaneous coronary intervention
,
Proportional Hazards Models
,
Recurrence
,
Registries
,
Retrospective Studies
,
Risk Factors
,
ST-elevation myocardial infarction
,
Suction
,
Thrombectomy - adverse effects
,
Thrombectomy - methods
,
Thrombectomy - mortality
,
thrombus aspiration
,
Time Factors
,
Treatment Outcome
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX